Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07466524 · ClinicalTrials.gov registry record

suPAR Michigan M2C2 Heterogeneity Validation Cohort Study

A clinical trial of COVID-19 and Acute Respiratory Distress Syndrome, sponsored by ViroGates A/S.

Completed
Registry status
367
Enrollment target
1
Study location

NCT07466524 is a study of COVID-19 and Acute Respiratory Distress Syndrome that has completed, run by ViroGates A/S. The registered enrollment target is 367 participants, below the 55,213-participant average among 203 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07466524, a study of COVID-19 and Acute Respiratory Distress Syndrome, has completed, sponsored by ViroGates A/S.

COMPLETED
Registry status
367 participants
Enrollment target
1
Study location

Study Summary

This is a retrospective, non interventional cohort study using stored plasma samples from appoximately 300 adults hospitalized with confirmed COVID 19. Baseline suPAR measured using the suPARnostic TurbiLatex assay on the Roche cobas c501.

Conditions Studied

COVID-19 Acute Respiratory Distress Syndrome Severe Respiratory Distress Syndrome

Interventions

  • DIAGNOSTIC_TEST suPARnostic® TurbiLatex Assay on Roche cobas c501

Study Locations (1)

Michigan

  • Michigan state university, Department of Biostatistics - Ann Arbor

Trial Details

FieldValue
Enrollment Target 367 participants
Start Date 2020-02-01
Est. Completion 2022-10-19

Sponsor

ViroGates A/S

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07466524

The ClinicalTrials.gov registry entry for NCT07466524 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 367 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,213-participant average among 203 other COVID-19 trials with a reported enrollment target (99% lower). The listed sponsor is ViroGates A/S, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which suPARnostic® TurbiLatex Assay on Roche cobas c501 is the first listed.

NCT07466524 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT07466524 about?

NCT07466524 is a clinical study titled "suPAR Michigan M2C2 Heterogeneity Validation Cohort Study". This is a retrospective, non interventional cohort study using stored plasma samples from appoximately 300 adults hospitalized with confirmed COVID 19. Baseline suPAR measured using the suPARnostic TurbiLatex assay on the Roche cobas c501.

What is the current status of trial NCT07466524?

This trial is currently completed. The enrollment target is 367 participants. The study started on 2020-02-01. Estimated completion is 2022-10-19.

What conditions does trial NCT07466524 study?

This clinical trial studies the following conditions: COVID-19, Acute Respiratory Distress Syndrome, Severe Respiratory Distress Syndrome.

What interventions are being tested in trial NCT07466524?

The interventions under investigation include: suPARnostic® TurbiLatex Assay on Roche cobas c501 (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT07466524?

This trial is sponsored by ViroGates A/S, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07466524 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

COVID-19

All registered trials for this condition

Acute Respiratory Distress Syndrome

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.